Education
About Us
Working with TipRanks
Follow Us
Enliven Therapeutics (ELVN)
NASDAQ:ELVN
ELVN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$11.67 - $30.03
Previous CloseN/A
Volume37.78K
Average Volume (3M)205.91K
Market Cap
$1.01B
Enterprise Value$940.95M
Total Cash (Recent Filing)$124.12M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.80
Next Earnings
May 08, 2025EPS Estimate
-0.5Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.91
Shares Outstanding48,859,165
10 Day Avg. Volume246,444
30 Day Avg. Volume205,911
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-20.30
P/FCF Ratio0.00
Enterprise Value/Market Cap0.93
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-9.03
Forecast
1Y Price Target
$37.67Price Target Upside85.66% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
---
Enliven Therapeutics News
PremiumCompany Announcements
Enliven Therapeutics Reports 2024 Financial Results
PremiumCompany Announcements
Enliven Therapeutics Reports Q3 Results and Clinical Progress---
Bulls Say, Bears Say
Bulls Say
Financial PositionThe company has a strong cash position with cash, cash equivalents, and marketable securities totaling $313.4 million, providing a cash runway into mid-2027.
Product DevelopmentEnliven Therapeutics is expected to provide additional Phase 1 data from their main asset ELVN-001 and initial data from their second program ELVN-002, which are key focuses for investors.
Bears Say
Market CompetitionThe HER2 program is in a competitive space with high development costs, and the market currently views it as a free option, indicating potential financial challenges.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ELVN FAQ
What was Enliven Therapeutics’s price range in the past 12 months?
Enliven Therapeutics lowest stock price was $11.67 and its highest was $30.03 in the past 12 months.
What is Enliven Therapeutics’s market cap?
Enliven Therapeutics’s market cap is $1.01B.
When is Enliven Therapeutics’s upcoming earnings report date?
Enliven Therapeutics’s upcoming earnings report date is May 08, 2025 which is in 53 days.
How were Enliven Therapeutics’s earnings last quarter?
Enliven Therapeutics released its earnings results on Mar 13, 2025. The company reported -$0.46 earnings per share for the quarter, beating the consensus estimate of -$0.515 by $0.055.
Is Enliven Therapeutics overvalued?
According to Wall Street analysts Enliven Therapeutics’s price is currently Undervalued.
Does Enliven Therapeutics pay dividends?
Enliven Therapeutics does not currently pay dividends.
What is Enliven Therapeutics’s EPS estimate?
Enliven Therapeutics’s EPS estimate is -0.5.
How many shares outstanding does Enliven Therapeutics have?
Enliven Therapeutics has 48,859,165 shares outstanding.
What happened to Enliven Therapeutics’s price movement after its last earnings report?
Enliven Therapeutics reported an EPS of -$0.46 in its last earnings report, beating expectations of -$0.515. Following the earnings report the stock price went up 2.218%.
Which hedge fund is a major shareholder of Enliven Therapeutics?
Currently, no hedge funds are holding shares in ELVN
---
Enliven Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$37.67 (85.66% Upside)
$37.67 (85.66% Upside)
Blogger Sentiment
Bullish
ELVN Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 206.4K Shares
Last Quarter.
Last Quarter.
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
65.36%
12-Months-Change
Fundamentals
Return on Equity
-30.98%
Trailing 12-Months
Asset Growth
11.45%
Trailing 12-Months
Company Description
Enliven Therapeutics
Enliven Therapeutics (ELVN) is a biopharmaceutical company dedicated to discovering and developing innovative therapies for patients with serious diseases. The company operates in the healthcare sector, focusing on cutting-edge research and development to bring novel treatments to market. Enliven Therapeutics aims to address unmet medical needs through its pipeline of therapeutic candidates, leveraging advanced scientific approaches to improve patient outcomes.
---
ELVN Stock 12 Month Forecast
Average Price Target
$37.67
▲(85.66% Upside)
Technical Analysis
Crinetics Pharmaceuticals
―
Bicycle Therapeutics
―
Immunovant
―
Context Therapeutics
―
Best Analysts Covering ELVN
1 Year
1 Year Success Rate
6/16 ratings generated profit
1 Year Average Return
+20.59%
reiterated a buy rating 2 days ago
Copying Sam Slutsky's trades and holding each position for 1 Year would result in 37.50% of your transactions generating a profit, with an average return of +20.59% per trade.
---